Noah P. Zimmerman
Noah P. Zimmerman has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Camille J. Delebecque
Verb Biotics LLC, Boston, MA, USA
3 shared publications - D. Keller
Keller Consulting Group, Beachwood, OH, USA
2 shared publications - Amy Wescott
Church & Dwight Co., Inc., W227N752 Westmound Dr., Waukesha, WI 53186, USA
1 shared publication - Annahita Ghassemi
Church & Dwight, Princeton, USA
1 shared publication - Arpita Aditya
Verb Biotics LLC, Boston, MA 02210, USA
1 shared publication - Azure Dominique Grant
People Science, Inc, Los Angeles, CA
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-14
The effects of a postbiotic supplement on biomarkers of microbiome, gastrointestinal, cardiometabolic, and immunometabolic health
The gut microbiome is increasingly recognised as a modifiable contributor to metabolic, immune, and stress-related physiology, yet many nutritional interventions produce broad microbial shifts that may be poorly tolerated. We investigated the effects of a fermented and pasteurised oat-based preparation (Keystone) on microbiome composition and selected biomarkers in a 4-week randomised, double-blind, placebo-controlled trial in generally healthy adults. Seventy-six participants completed the intervention (38 placebo, 38 Keystone). Stool samples collected at baseline and week 4 underwent shotgun metagenomic sequencing, and serum butyrate, IL-8, morning cortisol, albumin/globulin ratio, routine clinical chemistries, DASS-21, and SF-36 were assessed. The intervention did not affect alpha or beta diversity. In contrast, species-level analysis showed a distinct compositional signature, with enrichment of taxa including Akkermansia spp., Bacteroides intestinalis , Bifidobacterium pseudocatenulatum , and Anaerostipes caccae in the Keystone group, alongside lower abundance of several Haemophilus , Megasphaera , and Prevotella taxa relative to placebo (FDR < 0.001). Nominally significant baseline-by-treatment interactions were observed for morning cortisol ( ), IL-8 ( ), and albumin/globulin ratio ( ), while serum butyrate showed a near-significant trend ( ). SF-36 emotional well-being improved within the Keystone group. No adverse events were reported. These results indicate that Keystone was safe and well tolerated and selectively modulates the gut microbiome, with exploratory associations for host stress and inflammatory markers that offer key insights for future follow-up studies. Trial registration: The trial was IRB approved and registered with ClinicalTrials.gov NCT07527286.
- 20 July 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-14
Open AccessThe effects of a postbiotic supplement on biomarkers of microbiome, gastrointestinal, cardiometabolic, and immunometabolic health
The gut microbiome is increasingly recognised as a modifiable contributor to metabolic, immune, and stress-related physiology, yet many nutritional interventions produce broad microbial shifts that may be poorly tolerated. We investigated the effects of a fermented and pasteurised oat-based preparation (Keystone) on microbiome composition and selected biomarkers in a 4-week randomised, double-blind, placebo-controlled trial in generally healthy adults. Seventy-six participants completed the intervention (38 placebo, 38 Keystone). Stool samples collected at baseline and week 4 underwent shotgun metagenomic sequencing, and serum butyrate, IL-8, morning cortisol, albumin/globulin ratio, routine clinical chemistries, DASS-21, and SF-36 were assessed. The intervention did not affect alpha or beta diversity. In contrast, species-level analysis showed a distinct compositional signature, with enrichment of taxa including Akkermansia spp., Bacteroides intestinalis , Bifidobacterium pseudocatenulatum , and Anaerostipes caccae in the Keystone group, alongside lower abundance of several Haemophilus , Megasphaera , and Prevotella taxa relative to placebo (FDR < 0.001). Nominally significant baseline-by-treatment interactions were observed for morning cortisol ( ), IL-8 ( ), and albumin/globulin ratio ( ), while serum butyrate showed a near-significant trend ( ). SF-36 emotional well-being improved within the Keystone group. No adverse events were reported. These results indicate that Keystone was safe and well tolerated and selectively modulates the gut microbiome, with exploratory associations for host stress and inflammatory markers that offer key insights for future follow-up studies. Trial registration: The trial was IRB approved and registered with ClinicalTrials.gov NCT07527286.
- Open Access
- 7 July 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- p. 1-9
Mechanistic characterisation of a novel oat-based postbiotic: microbiome modulation, barrier protection, and wound healing.
Postbiotics, the inactivated microorganisms and their products derived from fermentation, represent an evolution in the rapidly growing biotics industry and extend health benefits without the need for bacterial viability. In this study, we explored the potential of a novel oat-based postbiotic to provide health benefits by modulating the host immune system and gut microbiome. Two Lactobacillus species, Lactiplantibacillus plantarum 276 and Lacticaseibacillus rhamnosus GG, were used together to ferment 15% oat flour for 24 h at 37 °C followed by pasteurisation and freeze-drying to produce the oat-based postbiotic (OP). OP (1 mg/ml) was used to pretreat a mammalian intestinal epithelial cell line (Caco-2) for 1 h before stimulation with TNF-α and IL-1β (10 ng/ml each). The immuno-modulatory and barrier-supporting effect of OP were evaluated by measuring transepithelial electrical resistance (TEER), wound healing, and expression of cytokines genes (IL-6 and CXCL-8) as well as in a nematode (Caenorhabditis elegans) model. OP protected intestinal barrier integrity as measured by TEER in Caco-2 cells and in the C. elegans model. IL-6 and CXCL-8 expressions in OP pretreated cells were upregulated and OP promoted significant wound closure within 24 h. OP also markedly modulated the human gut microbiome as demonstrated by a 6.48-fold increase in native Bifidobacterium spp. in the in vitro human faecal model. Findings of this study suggest that OP is a novel, safe, stable, and effective intervention for foundational gut health and overall wellness.
- 7 July 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- p. 1-9
Open AccessMechanistic characterisation of a novel oat-based postbiotic: microbiome modulation, barrier protection, and wound healing.
Postbiotics, the inactivated microorganisms and their products derived from fermentation, represent an evolution in the rapidly growing biotics industry and extend health benefits without the need for bacterial viability. In this study, we explored the potential of a novel oat-based postbiotic to provide health benefits by modulating the host immune system and gut microbiome. Two Lactobacillus species, Lactiplantibacillus plantarum 276 and Lacticaseibacillus rhamnosus GG, were used together to ferment 15% oat flour for 24 h at 37 °C followed by pasteurisation and freeze-drying to produce the oat-based postbiotic (OP). OP (1 mg/ml) was used to pretreat a mammalian intestinal epithelial cell line (Caco-2) for 1 h before stimulation with TNF-α and IL-1β (10 ng/ml each). The immuno-modulatory and barrier-supporting effect of OP were evaluated by measuring transepithelial electrical resistance (TEER), wound healing, and expression of cytokines genes (IL-6 and CXCL-8) as well as in a nematode (Caenorhabditis elegans) model. OP protected intestinal barrier integrity as measured by TEER in Caco-2 cells and in the C. elegans model. IL-6 and CXCL-8 expressions in OP pretreated cells were upregulated and OP promoted significant wound closure within 24 h. OP also markedly modulated the human gut microbiome as demonstrated by a 6.48-fold increase in native Bifidobacterium spp. in the in vitro human faecal model. Findings of this study suggest that OP is a novel, safe, stable, and effective intervention for foundational gut health and overall wellness.
- Open Access
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 615
Limosilactobacillus reuteri 3613-1 Delays Onset of Unconfirmed Urinary Tract Infections in Otherwise Healthy Women
Urinary tract infections (UTIs) impose a substantial burden on women’s health, and probiotics have emerged as an alternative strategy to support urogenital wellbeing. This study evaluated the antimicrobial properties of Limosilactobacillus reuteri 3613-1 and its ability to improve UTI outcomes in women with a history of recurrent uncomplicated UTIs. In vitro assays demonstrated that L. reuteri 3613-1 inhibited the growth of Escherichia coli isolates and proved superior inhibition of Gardnerella vaginalis and Candida albicans compared with a comparator L. reuteri strain, supported by confirmed reuterin production and genomic profiling. A randomized, double-blind, placebo-controlled clinical trial (n = 130) assessed daily supplementation with L. reuteri 3613-1 for 24 weeks. While the proportion, frequency, and intensity of confirmed UTIs did not differ significantly between groups, L. reuteri 3613-1 delayed the onset of the first UTI, reaching significance in participants with suspected while unconfirmed UTIs. Vaginal pH and vaginal microbiome composition remained stable and comparable between groups across the intervention. The product was safe and well tolerated. Overall, L. reuteri 3613-1 shows promise as a probiotic candidate with antimicrobial activity and potential to delay symptom onset in women susceptible to recurrent UTIs, warranting further investigation in larger studies.
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 615
Open AccessLimosilactobacillus reuteri 3613-1 Delays Onset of Unconfirmed Urinary Tract Infections in Otherwise Healthy Women
Urinary tract infections (UTIs) impose a substantial burden on women’s health, and probiotics have emerged as an alternative strategy to support urogenital wellbeing. This study evaluated the antimicrobial properties of Limosilactobacillus reuteri 3613-1 and its ability to improve UTI outcomes in women with a history of recurrent uncomplicated UTIs. In vitro assays demonstrated that L. reuteri 3613-1 inhibited the growth of Escherichia coli isolates and proved superior inhibition of Gardnerella vaginalis and Candida albicans compared with a comparator L. reuteri strain, supported by confirmed reuterin production and genomic profiling. A randomized, double-blind, placebo-controlled clinical trial (n = 130) assessed daily supplementation with L. reuteri 3613-1 for 24 weeks. While the proportion, frequency, and intensity of confirmed UTIs did not differ significantly between groups, L. reuteri 3613-1 delayed the onset of the first UTI, reaching significance in participants with suspected while unconfirmed UTIs. Vaginal pH and vaginal microbiome composition remained stable and comparable between groups across the intervention. The product was safe and well tolerated. Overall, L. reuteri 3613-1 shows promise as a probiotic candidate with antimicrobial activity and potential to delay symptom onset in women susceptible to recurrent UTIs, warranting further investigation in larger studies.
- Open Access
Efficacy of a Novel Lactiplantibacillus plantarum Strain (LP815TM) in Reducing Canine Aggression and Anxiety: A Randomized Placebo-Controlled Trial with Qualitative and Quantitative Assessment
Behavioral issues in domestic dogs represent a significant welfare concern affecting both canines and their caregivers, with prevalence rates reported to range from 34 to 86% across the population. Current treatment options, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, often present limitations including adverse effects and delayed efficacy. This randomized, placebo-controlled (maltodextrin) study investigated the effects of a novel Lactiplantibacillus plantarum strain (LP815TM) on canine behavioral concerns through gut–brain axis modulation. Home-based dogs (n = 40) received either LP815TM (n = 28) or placebo (n = 12) daily for 4 weeks, with behavioral changes assessed using the comprehensive Canine Behavioral Assessment & Research Questionnaire (C-BARQ) and continuous activity monitoring. After the intervention period, dogs receiving LP815TM showed significant improvements in aggression (p = 0.0047) and anxiety (p = 0.0005) compared to placebo controls. These findings were corroborated by objective activity data, which demonstrated faster post-departure settling, reduced daytime sleep, and improved sleep consistency in the treatment group. Throughout >1120 administered doses, no significant adverse events were reported, contrasting favorably with pharmaceutical alternatives. The concordance between our findings and previous research using different L. plantarum strains suggests a consistent biological mechanism, potentially involving GABA production and vagal nerve stimulation. These results indicate that LP815TM represents a promising, safe alternative for addressing common canine behavioral concerns with potential implications for improving both canine welfare and the human–animal bond.
Open AccessEfficacy of a Novel Lactiplantibacillus plantarum Strain (LP815TM) in Reducing Canine Aggression and Anxiety: A Randomized Placebo-Controlled Trial with Qualitative and Quantitative Assessment
Behavioral issues in domestic dogs represent a significant welfare concern affecting both canines and their caregivers, with prevalence rates reported to range from 34 to 86% across the population. Current treatment options, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, often present limitations including adverse effects and delayed efficacy. This randomized, placebo-controlled (maltodextrin) study investigated the effects of a novel Lactiplantibacillus plantarum strain (LP815TM) on canine behavioral concerns through gut–brain axis modulation. Home-based dogs (n = 40) received either LP815TM (n = 28) or placebo (n = 12) daily for 4 weeks, with behavioral changes assessed using the comprehensive Canine Behavioral Assessment & Research Questionnaire (C-BARQ) and continuous activity monitoring. After the intervention period, dogs receiving LP815TM showed significant improvements in aggression (p = 0.0047) and anxiety (p = 0.0005) compared to placebo controls. These findings were corroborated by objective activity data, which demonstrated faster post-departure settling, reduced daytime sleep, and improved sleep consistency in the treatment group. Throughout >1120 administered doses, no significant adverse events were reported, contrasting favorably with pharmaceutical alternatives. The concordance between our findings and previous research using different L. plantarum strains suggests a consistent biological mechanism, potentially involving GABA production and vagal nerve stimulation. These results indicate that LP815TM represents a promising, safe alternative for addressing common canine behavioral concerns with potential implications for improving both canine welfare and the human–animal bond.
- Open Access
- 24 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-12
Lactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study
The major inhibitory neurotransmitter gamma-aminobutyric acid or GABA plays a pivotal role in mood and sleep. GABA exerts sedative and anxiolytic effects both within the central nervous system and through the gut-brain axis, which has generated interest in the potential for gut GABA to modulate mood and sleep. Several bacterial strains can produce GABA, yet their real-world impacts are poorly understood. We investigated the impact of 2 doses of the strain Lactiplantibacillus plantarum Lp815 on anxiety, sleep, mood, quality of life, cognition, heart rate variability and adverse events in adults with mild to moderate anxiety over a 6-week period. The trial was structured as a double-blinded, randomised, placebo-controlled trial with optional open label extension. Participants were blindly assigned to receive either a placebo, 1 billion colony-forming units (CFU), or 5 billion CFU of the oral capsule per day. Participants completed biweekly anxiety, insomnia and cognition measures, daily mood, sleep, and quality of life surveys, and collected wearable heart rate variability. 83 individuals were evaluated, aged 39 ± 13 years, 63% female and 64% Caucasian. Participants receiving 5 billion CFU exhibited significantly lower anxiety (GAD-7) scores at weeks 4 and 6 compared to placebo (Kruskal-Wallis ). This result was clinically meaningful, with 68% of participants in the 5 billion CFU cohort exhibiting improvement by more than one category in their GAD-7 scores at week 6, compared to 37% in the 1 billion CFU group and 26% in the placebo group (e.g. from moderate to no anxiety) (Fisher’s exact test for 5 billion CFU vs Placebo). No serious adverse events occurred. A daily capsule containing 5 billion CFU Lp815 significantly reduced anxiety in a diverse cohort of adults at 4 and 6 weeks following daily consumption. GABA-producing probiotics may offer a safe option for anxiety reduction in people with mild to moderate anxiety. Trial Registration. The trial was IRB approved and registered with ClinicalTrials.gov (NCT06466603).
- 24 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-12
Open AccessLactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study
The major inhibitory neurotransmitter gamma-aminobutyric acid or GABA plays a pivotal role in mood and sleep. GABA exerts sedative and anxiolytic effects both within the central nervous system and through the gut-brain axis, which has generated interest in the potential for gut GABA to modulate mood and sleep. Several bacterial strains can produce GABA, yet their real-world impacts are poorly understood. We investigated the impact of 2 doses of the strain Lactiplantibacillus plantarum Lp815 on anxiety, sleep, mood, quality of life, cognition, heart rate variability and adverse events in adults with mild to moderate anxiety over a 6-week period. The trial was structured as a double-blinded, randomised, placebo-controlled trial with optional open label extension. Participants were blindly assigned to receive either a placebo, 1 billion colony-forming units (CFU), or 5 billion CFU of the oral capsule per day. Participants completed biweekly anxiety, insomnia and cognition measures, daily mood, sleep, and quality of life surveys, and collected wearable heart rate variability. 83 individuals were evaluated, aged 39 ± 13 years, 63% female and 64% Caucasian. Participants receiving 5 billion CFU exhibited significantly lower anxiety (GAD-7) scores at weeks 4 and 6 compared to placebo (Kruskal-Wallis ). This result was clinically meaningful, with 68% of participants in the 5 billion CFU cohort exhibiting improvement by more than one category in their GAD-7 scores at week 6, compared to 37% in the 1 billion CFU group and 26% in the placebo group (e.g. from moderate to no anxiety) (Fisher’s exact test for 5 billion CFU vs Placebo). No serious adverse events occurred. A daily capsule containing 5 billion CFU Lp815 significantly reduced anxiety in a diverse cohort of adults at 4 and 6 weeks following daily consumption. GABA-producing probiotics may offer a safe option for anxiety reduction in people with mild to moderate anxiety. Trial Registration. The trial was IRB approved and registered with ClinicalTrials.gov (NCT06466603).